Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders
Asset Value Investors Limited (“AVI”) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, “Rohto”), as a follow-up to its ongoing campaign, “Awakening Rohto”, launched last year and aimed at enhancing the company’s corporate value. AVI has published a detailed presentation on a dedicated website (www.AwakeningRohto.com).
AVI Urges Appointment of New TPIL Director
AVI, manager of the £1.3bn AVI Global Trust (AGT) and three other Shareholders, together representing over 18% of TPIL’s ordinary shares, requisitioned the board of TPIL on 18 January 2022 requiring the Board to convene an EGM at which Shareholders will be asked to vote on a resolution to appoint Richard Boléat as a new independent director of TPIL.
AVI Launches Public Website Highlighting MOL's Exploitation of Daibiru
Asset Value Investors Limited (“AVI” or “we”) today announced that it has launched a website highlighting the exploitation of Daibiru Corporation (TYO 8806) (“Daibiru”) by its parent company Mitsui O.S.K. Lines, Ltd. (TYO 9104) (“MOL”), and is requesting that Daibiru withdraws its support for MOL’s 2,200 yen tender offer and resumes negotiations with MOL to seek a higher purchase price.
AVI Urges Removal of Third Point's TPIL Director
Asset Value Investors Limited ("AVI") urges Shareholders to vote FOR the removal of Joshua L Targoff as a director of Third Point Investors Limited (TPIL) to indicate their support for AVI’s proposed discount control mechanism.
